Integrated transcriptomic analysis reveals lymphatic Icam1-mediated immune dynamics after myocardial infarction

Xue-Ting Chen1,2, Bei-Bei Hu3, Zhao Zhang1,2

  • 1College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.

Zoological Research
|June 4, 2026
PubMed

Insights

Intercellular adhesion molecule-1 (ICAM-1) in lymphatic endothelial cells (LECs) is crucial for resolving cardiac inflammation after myocardial infarction (MI). Its absence worsens injury by impairing immune cell clearance and promoting fibrosis.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Vascular Biology

Background:

  • Cardiac lymphatic vessels regulate immune responses and inflammation resolution post-myocardial injury.
  • Intercellular adhesion molecule-1 (ICAM-1) is key in leukocyte trafficking during inflammation.
  • The role of ICAM-1 in lymphatic endothelial cells (LECs) post-myocardial infarction (MI) is not well understood.

Purpose of the Study:

  • To investigate the function of ICAM-1 in LECs in the context of post-MI cardiac remodeling.
  • To elucidate the impact of LEC-specific ICAM-1 deficiency on the cardiac immune microenvironment after MI.

Main Methods:

  • Generated an LEC-specific ICAM-1 conditional knockout (cko) mouse model.
  • Utilized single-cell RNA sequencing and spatial transcriptomics to analyze cardiac tissue at multiple time points post-MI.
  • Performed cell-cell communication analysis to understand immune cell interactions.

Main Results:

  • LEC-specific ICAM-1 deletion exacerbated post-MI inflammation and fibrotic remodeling, indicating aggravated cardiac injury.
  • Transcriptomic analyses revealed significant alterations in cell composition, with expanded proinflammatory neutrophil and macrophage subsets.
  • Deletion of ICAM-1 in LECs disrupted immune cell trafficking via lymphatic vessels, impairing inflammatory cell clearance and amplifying immune imbalance.

Conclusions:

  • LEC ICAM-1 plays a critical role in regulating the immune microenvironment and tissue repair after myocardial infarction.
  • Targeting LEC ICAM-1 presents a potential therapeutic strategy for improving outcomes following MI.